Biostage, Inc. (BSTG) financial statements (2020 and earlier)

Company profile

Business Address 84 OCTOBER HILL ROAD
HOLLISTON, MA 01746
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1111146
Cash and cash equivalents1111146
Restricted cash and investments0   0  
Receivables      0
Prepaid expense0   000
Other current assets0   000
Other undisclosed current assets001100(0)
Total current assets:1222246
Noncurrent Assets
Operating lease, right-of-use asset00  
Property, plant and equipment0000011
Other undisclosed noncurrent assets  00   
Total noncurrent assets:1111011
TOTAL ASSETS:2232347
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:0000000
Accounts payable 000000
Accrued liabilities0   0  
Employee-related liabilities0      
Other undisclosed accounts payable and accrued liabilities0   0  
Debt00     
Derivative instruments and hedges, liabilities0000000
Other undisclosed current liabilities0011011
Total current liabilities:1111111
Noncurrent Liabilities
Long-term debt and lease obligation00     
Operating lease, liability00  
Other undisclosed noncurrent liabilities  00   
Total noncurrent liabilities:0000   
Total liabilities:1111111
Stockholders' equity
Stockholders' equity attributable to parent1121245
Common stock0000000
Additional paid in capital65646259585757
Accumulated deficit(64)(62)(60)(58)(56)(54)(52)
Total stockholders' equity:1121245
TOTAL LIABILITIES AND EQUITY:2232347

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(2)(2)(3)(2)(2)(2)(2)
Operating loss:(2)(2)(3)(2)(2)(2)(2)
Nonoperating income (expense)000000(0)
Other nonoperating expense      (0)
Net loss available to common stockholders, diluted:(2)(2)(2)(2)(2)(2)(2)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(2)(2)(2)(2)(2)(2)(2)
Comprehensive loss, net of tax, attributable to parent:(2)(2)(2)(2)(2)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: